HKT-500 Ketoprofen Topical Patch — Competitive Intelligence Brief

HKT-500 Ketoprofen Topical Patch (HKT-500 Ketoprofen Topical Patch) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Pain Management / Rheumatology.

phase 3 Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2) Pain Management / Rheumatology Small molecule

Target snapshot

HKT-500 Ketoprofen Topical Patch (HKT-500 Ketoprofen Topical Patch) — Hisamitsu Pharmaceutical Co., Inc.. Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
HKT-500 Ketoprofen Topical Patch TARGET	HKT-500 Ketoprofen Topical Patch	Hisamitsu Pharmaceutical Co., Inc.	phase 3	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Bromfenac 0.09 % Ophthalmic Solution	Bromfenac 0.09 % Ophthalmic Solution	Azienda USL Reggio Emilia - IRCCS	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Plain aspirin	Plain aspirin	Royal College of Surgeons, Ireland	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Ketoprofen Lysine Salt	Ketoprofen Lysine Salt	Dompé Farmaceutici S.p.A	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Ibuprofen 2%	Ibuprofen 2%	Berlin-Chemie AG Menarini Group	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
Diclofenac Sodium gel, 1%	Diclofenac Sodium gel, 1%	Glenmark Pharmaceuticals Ltd. India	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Ketorolac Tromethamine 0.45%	Ketorolac Tromethamine 0.45%	Bucci Laser Vision Institute	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class